Scotiabank downgraded Myriad Genetics (MYGN) to Sector Perform from Outperform with a $6 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics price target lowered to $4 from $9 at BofA
- Myriad Genetics price target lowered to $7 from $16 at Morgan Stanley
- Myriad Genetics price target lowered to $9 from $12.50 at Piper Sandler
- Hold Rating Maintained for Myriad Genetics Amid Revenue Cuts and Strategic Uncertainty
- Myriad Genetics Faces Challenges Amid Prenatal Testing Growth